



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES

Drug Utilization Review Board Meeting Minutes

September 19, 2012

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members Present:

Ernest Miller, D.O., Chairman
Scott Brown, R.Ph., Co-Chairman
Myra Chiang, M.D.
Randall James, D.O.
Lester Labus, M.D.
KC Lovin, PA-C
Mary Nemeth-Pyles, M.S.N., R.N., C.S.
Pat Regan, PharmD
Kerry Stitzinger, R.Ph.
Chris Terpening, PharmD, Ph.D.
John R. Vanin, M.D.

Members Absent:

Greenbrier Almond, M.D.
David Elliott, PharmD

DHHR/BMS Staff Present:

James Becker, MD, Medical Director
Vicki Cunningham, R.Ph, DUR Coordinator
Peggy King, Pharmacy Director
Gail Goodnight R.Ph, Drug Rebate Director
Bill Hopkins, Pharmacy Operations Manager

Contract Staff:

Steve Small, M.S., R.Ph., Director, Rational Drug Therapy Program
Eric Sears, R.Ph., Molina Medicaid Solutions
Douglas Brink, PharmD, Xerox State Healthcare
Chris Andrews, PharmD, Magellan Medicaid Administration
Giovanni Perri, M.D., Magellan Medicaid Administration
Victoria Mariani, RN, Xerox State Healthcare

I. INTRODUCTIONS

Dr. Ernest Miller, Chairman, welcomed everyone to the Board meeting. Members of the Board and interested parties introduced themselves.

II. APPROVAL OF THE MAY 23, 2012, MINUTES

A motion was made to accept the minutes of the May 23, 2012, DUR Board meeting. The motion was seconded and passed unanimously.

III. OLD BUSINESS

A. Letter to Top Opioid Prescribers Outcome

Dr. Brink, Xerox, reviewed data and outcomes from the Letter to the Top Opioid Prescribers intervention. Dr. Becker discussed the targeted intervention and relayed some comments he had received from targeted prescribers. The data shows a modest drop in opioid prescriptions written by the targeted prescribers. He requested that another report be generated and shared with the Board in six months. A motion was made for Xerox to complete the second six month follow up, the motion was seconded, and was approved.

See Attachment A

B. POS Oncology Drugs-Utilization and Cost

Ms. Cunningham presented information which was requested by the Board at the May 2012, DUR meeting regarding the utilization and cost of the oral oncology drugs. A motion was made to implement the prior authorization (PA) criteria and limits presented by Ms. Cunningham with follow up data in 6 months. The motion was seconded, all were in favor and the motion was approved.

See Attachment B

IV. NEW BUSINESS

A. Updates from August 15, 2012, P&T Committee Meeting

The Board reviewed the changes and additions made to the Preferred Drug List and agreed that no changes to prior authorization (PA) criteria were required.

See Attachment C

B. Proposed Criteria Changes for the January 1, 2013, PDL

1. Lyrica-Proposed Step Therapy-

Draft step therapy for Lyrica was presented by Ms. Cunningham.

a. Dr. Perri spoke to the Board regarding Lyrica and its role in the treatment of chronic pain patients. He also shared information about the implementation of a step therapy program for Lyrica by Michigan Medicaid.

b. Letters of comment on the proposed step therapy for Lyrica were reviewed by the Board.

c. The Board requested that point three of the PA criteria be clarified by removing the word *intolerance*, and replacing it with *an exception to the PA criteria*. The Board suggested putting limits on both gabapentin

and Lyrica and approving the least expensive dosage form. A motion was made to approve the step therapy criteria with the above changes; the motion was seconded and approved.

See Attachment D

2. Stimulants-Criteria for Adults-

Ms. Cunningham presented proposed changes for the prior authorization criteria for stimulants for adults (age 21 and older). The Board requested the following changes be made:

- a. Appropriate diagnosis be changed to documented diagnosis,
- b. Remove the condition antidepressant abuse,
- c. Add a fourth criterion stating that failure with Strattera and a long acting stimulant will be required before a short acting agent will be approved,
- d. Grandfather patients who are currently on long acting stimulants with documented diagnoses.

A motion was made to accept the proposal with the changes incorporated; the motion was seconded and approved.

See Attachment E

3. Venlafaxine Dosage Limitations-

Ms. Cunningham presented a graph which showed the number of members taking venlafaxine and the dose they are currently receiving. A motion was made to follow the FDA approved dosing recommendations and require a prior authorization for doses of venlafaxine above 375 mg/day. The motion was seconded, all were in favor and the motion was approved.

See Attachment F

4. Antipsychotic Duplication Edits-

Ms. Cunningham reported on the implementation of the Severity Level 1 Edit for duplication of atypical antipsychotics, first generation antipsychotics, or combinations of the two types of antipsychotics.

V. REPORTS

A. Xerox State Healthcare- Dr. Brink, Xerox State Healthcare, discussed recent Retrospective DUR activities.

1. The DUR Capsules newsletter, which focused on the new oral anticoagulant agents, was mailed in June 2012, to 4,661 providers.
2. The hyperlipidemia population-based educational intervention was mailed in June 2012 to 549 providers targeting 1,876 patients.

3. The depression management population-based educational intervention is in progress
4. The atypical antipsychotic newsletter is in progress.
5. Dr. Brink discussed outcomes of the polypharmacy and fibromyalgia targeted interventions.

See Attachment G

Dr. Brink proposed two population based educational interventions for prescribers: Atypical Antipsychotics: Coordination of Care and Benzodiazepine Anxiolytic Duration of Use in Adults. The Board requested the following changes be made to the benzodiazepine intervention: **1)** Modify the performance indicator including overdose or poisoning with abuse and **2)** Exclude seizure disorder from the exception criteria. A motion was made to accept both interventions with the requested changes; the motion was accepted unanimously and approved.

See Attachment H

B. Molina Medicaid Solutions- Eric Sears, Molina Medicaid Solutions, gave an overview of the DUR Second Quarter 2012 Report.
See Attachment I

C. Rational Drug Therapy Program- Steve Small, Director of the Rational Drug Therapy Program (RDTP), distributed a handout of his slide presentation. Mr. Small summarized the prior authorization process and top edits and overrides for June 2012, July 2012, and August 2012.
See Attachment J

VI. OTHER BUSINESS-OPEN TO THE FLOOR

Ellen Hale from the Love Family Practice Group in Beckley spoke about concerns of the group regarding proposed step therapy for Lyrica.

VII. NEXT MEETING AND ADJOURNMENT

A motion was made and seconded that the meeting be adjourned. The meeting was concluded at 6:00 p.m. The next meeting will be held on Wednesday, November 28, 2012 from 4:00 p.m.-6:00 p.m.

Respectfully submitted,

Victoria Mariani R.N., Xerox State Health